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Objective: Smoking is the major risk factor associated with the development and progression of peripheral arterial disease
(PAD). To establish the best estimate of the effect of smoking, smoking cessation, and the dose-response relationship on
the patency of lower extremity bypass grafts, we performed a systematic review.
Methods: A search of medical articles and reviews relating to the influence of smoking on the patency of arterial
reconstructive grafts in patients with PAD was made. Studies considered for inclusion were those that evaluated the
influence of smoking on the primary, secondary, or cumulative patency rates of arterial reconstructive surgery in the lower
extremities in patients with PAD. Primary data were used to calculate summary estimates with standard meta-analysis
techniques.
Results: The 29 eligible studies included 4 randomized clinical trials, 12 prospective studies, and 13 retrospective
studies. The effect of smoking on graft patency in the randomized clinical trials and other prospective studies had a
3.09-fold (2.34 to 4.08; P <.00001) increase in graft failure. A comparison of patency rates among all studies that
used autogenous or polyester grafts showed no difference. A clear dose-response relationship was present, with a
decreased patency in heavy smokers compared with moderate smokers. Smoking cessation restores patency rates
toward the never smokers group.
Conclusion: Continued smoking after lower limb bypass surgery results in a threefold increased risk of graft failure.
Smoking cessation, even if instigated after the operation, restored graft patency towards the patency of never smokers.
These results indicate that adequate smoking cessation strategies in patients eligible for lower limb bypass surgery are of
utmost importance. ( J Vasc Surg 2005;42:67-74.)Smoking is the major risk factor associated with the
development and progression of peripheral arterial disease
(PAD).1,2 Nearly all patients who require bypass surgery
have accumulated a considerable number of pack-years of
smoking. Often, patients with PAD appear to be less suc-
cessful in smoking cessation compared with patients after a
myocardial infarction.3,4
Numerous studies have been published on the influ-
ence of smoking on the results of graft patency in peripheral
vascular reconstructive surgery.2 Most of these studies
show a negative effect of smoking on graft patency, but the
differences in effect-size are substantial. The necessity to
adequately summarize the available data to define an appro-
priate evidence-based approach with respect to the influ-
ence of smoking and smoking cessation on graft patency
has long been recognised.5
To establish the best estimate of the effect of smoking
on the patency of lower extremity bypass grafts, we per-
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doi:10.1016/j.jvs.2005.03.024formed a systematic review. We also explored a possible
dose-response relationship and the effect of smoking cessa-
tion in our meta-analysis.
METHODS
The literature search, selection of studies, the inclusion
and exclusion of studies, the data extraction, and data
analysis were performed by two authors independently
(EW, MP).
Search strategy. A search of medical articles and re-
views relating to the influence of smoking on the patency of
arterial reconstructive grafts in patients with PAD from
1950 to 2004 was made in Medline, SUMsearch, the
Cochrane Library, and PubMed. Search terms (MESH and
free text) included peripheral arterial disease, peripheral
vascular disease, claudication, smoking, nicotine, tobacco,
patency, graft, bypass, stenosis, occlusion, arterial recon-
struction, lower extremities, vascular surgery, arterial sur-
gery and angioplasty. A manual search of reference lists for
relevant articles was also conducted.
Selection criteria. Studies considered for inclusion
were those that evaluated the influence of smoking on the
primary, secondary, or cumulative patency rates of arterial
reconstructive surgery in the lower extremities in patients
with PAD. Graft patency was analyzed with pulse examina-
tion, Doppler studies, and arteriography, if necessary. No
selection was made between graft materials. Studies were
excluded when graft patency rates in smokers had not been
adequately separated from nonsmokers. Also studies that
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or endarterectomies were excluded.
Data extraction. Data from the included studies were
extracted using a standardized form and summarized in
tabular format. Each eligible study was assessed for design
(prospective vs retrospective). The extracted data for smok-
ers and nonsmokers included number, sex, and duration of
follow-up of patients; graft patency, material, and location;
smoking substance, intensity, and assessment of smoking
Table I. Characteristics of included studies
Study Pat. Sex Follow- up Gra
Randomized controlled trials
Abbott7 244 3 yr PTF
Burger13 136 77M, 59F 2 yr ASV
Green20 240 5 yr PTF
Powell45 250 1 yr ASV
Prospective studies
Ameli8 105 9 m NR 
Cheshire14 46 1 yr ASV
Giswold16 55 46M, 9F 13 m RVG
Greenhalgh23 64 3-5 yr ASV
Herring25 161 D 
Lam30 229 P, A
Provan48 326 215M, 111F 5 yr ASV
Robicsek51 187 6 m-10 yr D 
Rutherford54 249 3 yr RVG
AS
Wiseman61 93 64M, 29F 2 yr P 
Wiseman62 157 1 yr ASV
Wray63 50 3-6 yr D 
Retrospective studies
Ameli9 121 5 yr ASV
U
Ameli10 73 5 yr ASV
U
Gentile15 93 55M, 38F 21m ASV
Hall24 195 169M, 26F 3 yr ASV
King28 290 141M, 41F 3 yr RVG
Miyazaki39 496 30.8 m PTF
Myers40 217 6 m-5 yr D, A
Nevelsteen42 792 10 yr D 
Powell46 250 1 yr ASV
Prendiville47 114 76M, 38F 3 yr PTF
Ramsburgh49 123 100M, 23F 2 yr RVG
Saad55 40 50 m P 
Sayers56 90 PTF
M, Male; F, female; cig/d, cigarettes per day; p/d, packs of cigarettes per day
smokers; Q, questioned; T, thiocyanate; COHb, carboxyhemoglobin; ASV
RVG, reversed; vein graft; P, polyester; BV, bovine vein; AK, above knee; Bstatus (questionnaire vs biochemical markers).Data analysis. Where possible, outcome data—ex-
pressed in terms of patency or relative risk—were used with
never smokers as the reference group. If this was not
available, the nonsmokers group (never and former smok-
ers together) was used. Different patency outcomes in the
various graft materials were taken into account in the
analysis. Primary data were used to calculate summary
estimates with standard meta-analysis techniques. The het-
erogeneity between studies was assessed with a 2 test,
terial Graft location Smoking intensity
Smoking
assessment
Fem-pop, AK No, C Q
E Fem-pop, AK No, C Q
Fem-pop, AK N, Fo, C:1 p/d,
1 p/d
Q
Fem-pop, AK No, C Q
A-fem No, C Q
E Infrainguinal No, C COHb
Fem-pop-tib-
ped
No, C Q
A-iliac, Fem-
pop
No, C COHb
Ax-fem, Ax-
fem-fem
No, C Q
Infrainguinal No, C Q
E Fem-pop N, Fo, C Q
A-iliac, A-fem N, Fo, C:1 p/d,
1 p/d
Q
FE,
V
Infrainguinal No, C Q
Fem-pop No, C COHb, T
Fem-pop No, C COHb, T
A-fem No, C: cig/d Q
E, Fem-pop, Fem-
tib
No, C: 1-5, 6-15,
16-25, 25
cig/d
Q
E, Fem-pop No, C: 1-5, 6-15,
16-25, 25
cig/d
Q
 Fem-pop, Fem-
tib-ped
No, C Q
NR No, C Q
Ax-fem, Ax-
fem-fem
No, C: 1-15,
15 cig/d
Q
Fem-pop, AK No, C Q
A-fem, Fem-
pop, Fem-tib
No, C: 1- 5, 6-
15, 16-25,
25 cig/d
Q
A-fem, A-bifem No, C Q
Fem-pop N, Fo, C COHb, T
AK No, C Q
, P Fem-pop, BK No, C Q
Fem-pop No, C Q
Infrainguinal,
AK
N, Fo, C Q
ever smoker;No, never and former smokers; Fo, former smokers; C, current
genous saphenus vein; PTFE, polytetrafluoroethylene; UV, umbilical vein;
low knee; A, aorta; NS, not significant; NR, not reported.ft ma
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RESULTS
The literature search resulted in the identification of 58
potentially eligible articles.6-63 Of these 29 had to be
excluded.6,11,12,17-19,21,22,26,27,29,31-38,41,43,44,50,52,53,57-60
Reasons for this were the absence of separate data on
smokers and nonsmokers (n  16), only on critical isch-
emia (n  1), only on reoperations after graft failure (n 
3), or the data on angioplasty and grafts had not been
separated (n  3). Three articles, written in Polish, Serb,
and Russian, were not included because they could not be
retrieved. Two articles, describing the same study popula-
tion were analyzed, and only those with the most extensive
data on the influence of smoking have been included.27,28
Two articles provided identical information and only one
was included.22,23 One review article was identified that
described two reports on the subject and therefore only the
cited articles have been included in the analysis.58 No
meta-analyses or systematic reviews were identified.
The 29 eligible studies included 4 randomized clinical
trials that randomized patients to different types of grafts,
Table II. Overall graft patency in nonsmokers versus smo
Study
Number
nonsmokers
Patency nonsmoke
n (%)
Randomized clinical trials
Powell45 19 16 (84%) 
Prospective studies
Ameli8 50 44 (88%) 
Cheshire14 29 23 (79%) 
Giswold16 105 88 (84%) 
Greenhalgh23 39 38 (97%) 
Herring25 10 5 (50%) 
Provan48 20 14 (70%) 
Rutherford54 84 57 (68%) 
Wiseman61 NR NR (78%) 
Wiseman62 86 72 (84%) 
Wray63 16 16 (100%) 
Subtotal 458 373
Common effect Peto OR, 3.09 (95% CI, 2.34-4.08
OR, 3.23 (95% CI, 2.39-4.35; P 
Retrospective studies
Amel9 50 44 (88%) 
Ameli10 76 43 (56%) 
Hall24 37 30 (81%) 
Nevelsteen42 453 249 (55%) 
Powell46 NR NR (89%) 
Powell46 NR NR (84%) 
Prendiville47 33 22 (66%) 
Ramsburgh49 46 29 (62%) 
Sayers55 10 7 (75%) 
Subtotal 705 424
Common effect Peto OR: 1.99 (95% CI, 1.62-2.47
OR: 2.02 (95% CI, 1.62-2.52; P 
Overall common effect Peto OR: 2.35 (95% CI, 1.98-2.78
OR: 2.39 (95% CI, 2.00-2.85; P 
Total overall 1,163 797
NR, Not reported; NS, not significant; OR, odds ratio.12 prospective studies, and 13 retrospective studies. Therandomized clinical trials are treated in the meta-analysis as
prospective studies. Details of the included studies are
summarized in Table I.
Graft patency in smokers versus nonsmokers.
Eleven prospective and nine retrospective studies provided
data on the influence of smoking on the general patency of
grafts (Table II). All but two retrospective studies showed a
significant decrease in graft patency in smoking patients.
Studies providing primary data on the number of smokers
and nonsmokers on graft patency have been included in the
meta-analysis. One prospective and one retrospective study
did not provide the number of patients and were excluded
from the summary estimates.46,61
The effect of smoking on graft patency in the prospec-
tive studies had a 3.09-fold (95% confidence interval [CI],
2.34 to 4.08; P  .00001) increase in graft failure (Table
III). The retrospective studies showed a 1.99-fold (95% CI,
1.61 to 2.47; P .00001) increase in graft failure (Table
III). The overall effect of smoking on graft patency, taking
prospective and retrospective studies into account, showed
a 2.35-fold (95% CI, 1.98 to 2.78) increase in risk of graft
failure (Table III). The analyzed studies showed no corre-
lation between study size and patency outcome (no statis-
Number
smokers
Patency smokers
n (%) P Patency
231 150 (65%) .02 Primary
55 34 (62%) .001 Primary
17 7 (39%) .016 Primary
68 43 (63%) .02 Primary
25 14 (56%) .001 Primary
24 8 (33%) NR Primary
57 19 (33%) .001 Primary
162 83 (51%) .05 Primary
NR NR (57%) .05 Primary
71 45 (63%) .02 Primary
30 21 (70%) .05 Secondary
740 424
 .00001)
01)
55 34 (62%) 0.045 Primary
60 29 (49%) NS Primary
172 119 (69%) 0.05 Primary
339 125 (37%) 0.05 Primary
NR NR (67%) 0.05 Primary
NR NR (63%) 0.02 Primary
81 32 (40%) 0.05 Primary
102 63 (62%) NS Primary
80 32 (40%) 0.001 Secondary
889 434
.00001)
01)
.00001)
1)
1,629 858kers
rs
; P 
.000
; P 
.000
; P 
.0000tical heterogeneity detected).
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termine the smoking status of the included patients, found
more outspoken differences between patency rates (3.81;
95% CI, 2.34 to 6.21), than studies that had interviewed
the patients about their smoking habits (2.19; 95%CI, 1.83
to 2.63).
There was no difference between studies with a
follow-up period of2 years (2.50; 95% CI, 1.78 to 3.49),
or studies with a follow-up period of 2 years (2.28; 95%
CI, 1.87 to 2.79).
Six studies did not provide primary data, but five re-
ported a higher risk of graft failure in smokers, which was
significant in three. The four prospective studies showed an
increased relative risk of 2.5 (P  .0017), 1.28 (95% CI,
0.64 to 2.55), 4.72 (95% CI 2.5 to 8.85; P  .001), and
1.72 (95% CI, 0.93 to 3.18; P  .008).8,13,16,30 The two
retrospective studies showed an increased risk in smokers of
1.59 (95% CI, 1.01 to 2.52; P  .046) and 0.99.39,55
Early graft flow disturbances are associated with future
graft failure. This was analyzed in one study that showed a
significant increase in early flow disturbances in the grafts of
smokers.15
Three prospective studies evaluated the additional ef-
fect of age combined with smoking on graft patency. All
studies showed that smokers 65 years old have a higher
risk of graft failure than do older smokers.7,9,20
Table III. The influence of smoking on graft patency in p
OR, Odds ratio; CI, confidence interval.The effect of smoking on the patency of differentgraft materials. Three prospective and two retrospective
studies looked explicitly into the influence of smoking on
different graft materials (Table IV).9,25,45,46,48 All, except
one small prospective study that used polyester grafts,
showed a decreased patency in grafts of smoking patients.
The remaining studies compared autogenous saphenus
vein with prosthetic femoropopliteal grafts. The two stud-
ies that provided primary data for a graft preference analysis
showed no difference in the effect of smoking on graft
patency between autogenous or polyester grafts in smoking
patients (0.94; 95% CI, 0.58 to 1.53).9,45 A comparison of
patency rates between all studies that used autogenous or
polyester grafts showed no difference in the effect of smok-
ing in polyester grafts (2.07; 95% CI, 1.62 to 2.65; P 
.0001) compared with autogenous grafts (2.78; 95% CI,
1.98 to 3.92; P  .0001) (Tables V and VI).
Smoking dose response and smoking cessation.
One prospective and two retrospective studies evaluated a
possible smoking dose-response relationship on graft pa-
tency.38,40,51 All three studies showed a clear dose-
response relationship, with a decreased patency in heavy
smokers compared with moderate smokers (Table VII).
Three studies evaluated the influence of smoking ces-
sation on graft patency.40,48,51 Smoking cessation was in-
stigated from the time of the bypass surgery during the
hospital stay. The difference in graft patency in former
ective and retrospective studiesrospsmokers compared with current smokers was significantly
uoroe
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rates in former smokers were comparable with the never
smokers group.
DISCUSSION
Patency of grafts in smokers versus nonsmokers.
Table IV. Patency in different graft materials
Study
Graft
material
Number
nonsmokers
Patency nonsm
n (%)
Randomized Clinical Trials
Powell45 ASV 13 11 (84%)
P 6 5 (87%)
Prospective studies
Herring25 D seeded 3 3 (100%
D unseeded 7 2 (30%)
Provan48 ASV 20 14 (70%)
PTFE NR NR (70%)
Retrospective studies
Ameli9 ASV 36 27 (74%)
P 40 14 (35%)
Powell46 ASV NR NR (89%)
P NR NR (84%)
ASV, Autogenous saphenus vein; P, polyester, D, Dacron; PTFE, polytetrafl
Table V. Patency rates in polyester grafts in smokers versu
OR, Odds ratio; CI, confidence interval.
Table VI. Patency rates in autogenous grafts in smokers v
OR, Odds ratio; CI, confidence interval.Continued smoking after lower limb bypass surgery resultsin a threefold increased risk of graft failure and a number
needed to harm of only four. This indicates that in smokers,
57% (95% CI, 50% to 64%) of graft failure can be attributed
to smoking. The ability of smokers to deceive their doctors
about their continued smoking habit may underestimate
the true incidence of smokers. One quarter of patients
Number
smokers
Patency smokers
n (%) P Patency
144 91 (63%) .02 Primary
87 59 (68%) .05 Primary
15 3 (20%) .05 Primary
9 4 (41%) NS Primary
57 24 (42%) .001 Primary
NR NR (16%) .001 Primary
28 17 (60%) NR Primary
32 12 (39% NR Primary
NR NR (67%) .05 Primary
NR NR (63%) .02 Primary
thylene; NR, not reported, NS, not significant.
nsmokers
non-smokersokers
 
) 
 
 
 s noersusundergoing femoropopliteal bypass surgery are covert
JOURNAL OF VASCULAR SURGERY
July 200572 Willigendael et alsmokers.9 Indeed, studies that used biochemical smoking
markers to determine the smoking status of the included
patients found more outspoken differences in patency rates
(relative risk [RR], 3.8) between smokers and nonsmokers
than studies that based smoking status solely on the patient
responses (RR, 3.1). Because only a minority of the present
studies used biochemical makers, it is likely that the true
influence of smoking on graft patency is even larger than
reported in this analysis.
The effect of smoking on the patency of different
graft materials. There was no difference between autog-
enous or polyester graft patency in smoking patients. This
absence of a preference in graft material is not unexpected.
In a recent meta-analysis, no clear evidence was present for
a possible preference in femoropopliteal graft materials.64
Dose response and the effect smoking cessation.
Although a dose-response relationship for smoking on graft
patency was present, no evidence exists that graft patency is
improved by reducing the number of daily cigarettes. Only
three studies (one prospective, two retrospective) reported
on the subject regarding graft patency by using a question-
naire for the patients’ smoking habits. Nevertheless, it is
likely that the effect is congruent with other atherosclerotic
diseases such as stroke and coronary artery disease, where a
clear dose-response exists.4,65 A possible underreporting by
smokers on the duration of smoking and the number of
daily cigarettes is indeed more than likely. However, this is
a conservative bias, therefore the visible dose-response re-
lationship is valid, although potentially underestimated.
Smoking cessation does seem to bring about a large
improvement in graft patency. Most studies reported on
smokers who had quit smoking after a peripheral bypass
operation. This implicates that smoking cessation, even if
started after the operation, benefits graft patency.
Limitations. Although 58 potentially eligible studies
were found, only half could be included. The reason for
studies not to present separate data on graft patency differ-
ences between smokers and nonsmokers could be caused
by a tendency not to report nonsignificant findings. This
could be a potential source of bias. On the other hand, the
consistency of the data and the absence of statistical heter-
ogeneity in the analysis suggest that the effect of this bias is
Table VII. Dose response in current, former, and never s
Study Graft location
Patency never
smokers N (%)
Pa
sm
Prospective
Robicsek51 A-iliac, A-fem 10 (100%) 86 (9
Retrospective
King28 Ax-fem, Ax-fem-fem 17 (94%) NR 
Myers40 A-fem, Fem-pop,
Fem-tib 
25 (90%) 32 (
50 (
Provan48 A-fem 12 (70%) 67 (8
A, Aorta; NR, not reported.likely to be small.Future implications. Because the patency outcome
differences between smokers and nonsmokers are clearly in
favor of the nonsmokers, there should be at least additional
patient information before vascular surgery about the con-
sequences of smoking and the subsequent risk of premature
graft failure. More important, patients should receive ex-
pert help and aid to stop smoking before vascular surgery.
CONCLUSION
Continued smoking after lower limb bypass surgery
results in an at least a threefold increased risk of graft failure.
Smoking cessation, even if instigated after the operation,
restored graft patency towards the patency of never smok-
ers. These results imply that adequate smoking-cessation
strategies in patients eligible for lower limb bypass surgery
are of the utmost importance.
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